EGIS-8332

 

Topic mentions per year

Topic mentions per year

2004-2011
012320042011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Currently there is no treatment for juvenile Batten disease, a fatal childhood neurodegenerative disorder caused by mutations in… (More)
Is this relevant?
2011
2011
Mutations in the CLN3 gene cause juvenile Batten disease, a fatal pediatric neurodegenerative disorder. The Cln3-knockout (Cln3… (More)
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Juvenile Batten disease, caused by mutations in the CLN3 gene, is a fatal, incurable neurodegenerative disorder in children. The… (More)
Is this relevant?
2008
2008
Although emerging number of data supports the role of glutamate receptors and the potential of their antagonists in anxiety… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Review
2008
Review
2008
The neuronal ceroid lipofuscinoses (NCLs or Batten disease) are a group of at least nine autosomal recessively inherited… (More)
Is this relevant?
2007
2007
BACKGROUND AND PURPOSE Blockade of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors is a good treatment… (More)
Is this relevant?
2007
2007
We observed in vitro neuroprotective and AMPA/kainate receptor antagonist effects of the new 2,3-benzodiazepine derivative EGIS… (More)
Is this relevant?
2006
2006
EGIS-8332 and GYKI 53405 are selective, non-competitive AMPA (2-amino-3[3-hydroxy-5-methyl-4-isoxazolyl] propionic acid… (More)
Is this relevant?
2005
2005
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists have been shown to have neuroprotective… (More)
Is this relevant?
2004
2004
Antagonists of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors can considerably reduce brain damage… (More)
Is this relevant?